多瑞吉治疗中重度癌症疼痛患者54例疗效观察

Observation of Therapeutic Efficacy on Durogesic in 54 Patients with Moderate or Severe Cancer Pain

目的:观察多瑞吉(芬太尼透皮贴剂)在治疗中重度癌症疼痛中的效果和不良反应。方法:54例具有中重度癌痛的患者使用多瑞吉治疗,初治患者最初剂量为25μg/h,以前曾用过强阿片类药物的患者根据用药情况进行多瑞吉剂量转换。用药后观察24 h,疼痛缓解欠佳时进行剂量滴定,按照25μg/h增加剂量,直至疼痛缓解。治疗时严密观察药物剂量、疗效、副作用、药物依赖性等,填写标准疼痛观察表,采用VAS评分。结果:本组患者总缓解率94.4%(51/54),其中完全缓解率为79.6%(43/54),明显缓解率为14.8%(8/54)。主要的不良反应是便秘、头晕、恶心、嗜睡、皮肤痛痒等,其发生率较低。无呼吸抑制、成瘾发生。结论:多瑞吉治疗中重度癌性疼痛疗效确切,使用方便,副作用轻,能提高疼痛患者生活质量。

Objective：To observe the efficacy and adverse reaction of Durogesic （transdermal fentanyl） in treatment of patients with moderate or severe cancer pain. Methods： Fifty-four patients with moderate or severe cancer pain were treated with Durogesic. The initial dosage of initially treated patients was 25μg/h. The patients treated with strong opioids previously were carried out the dose conversion of Durogesic according to the conditions of administration. And then the patients were to be observed for 24 h after the administration. If the pain alleviation was not ideal, the dosage titration would be carried out and the dosage would be increased by 25μg/h till the pain was alleviated. The physicians should observe dministration dosage, efficacy, side effects and drug dependence carefully and fill in a standardized questionnaire form. which was evaluated by the VAS score. Results： The total alleviating rate of the patients in the group was 94.4%（51/54） ,the complete alleviating rate was 79.6% （43/54） and the marked alleviating rate was 14.8% （8/54）among them. The chief adverse reactions were constipation, dizziness, nausea, lethargy and itch of skin and so on and the incidence rate was lower. No respiratory inhibition and addiction occurred. Conclusion： The efficacy of Durogesic is precise in treatment of patients with moderate or severe cancer pain. It is easy to use and the adverse effect is mild. Durogesic can also improve the quality of life of the patients with cancer pain.